Research & Development: Page 20
-
Stock via Getty Images
After numerous setbacks, here’s where the Huntington’s pipeline stands
A look at emerging treatments and where there’s hope for patients.
By Kelly Bilodeau • Nov. 7, 2022 -
Stock via Getty Images
Acumen cruises into the fast lane with novel Alzheimer’s treatment
The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.
By Meagan Parrish • Nov. 3, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Christopher Furlong / Staff via Getty Images
‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected
Toxoplasmosis is carried by about a third of the world’s population, but effective drugs are lacking — now researchers have discovered a key infection element that could lead to better treatment.
By Michael Gibney • Nov. 3, 2022 -
Retrieved from Google image.
While DCTs get all the hype, some industry insiders say the future is a digital hybrid
Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.
By Michael Gibney • Nov. 1, 2022 -
Spencer Platt via Getty Images
Q&ATuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that
The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.
By Alexandra Pecci • Nov. 1, 2022 -
iStock via Getty Images
Tips for tackling trial recruitment and retention woes in oncology
How new tools are helping companies find and keep cancer patients in clinical studies.
By Kelly Bilodeau • Oct. 31, 2022 -
iStock via Getty Images
Q&A // Biotech SpotlightThe first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology
Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.
By Karissa Waddick • Oct. 27, 2022 -
Permission granted by Biogen
Riches, rags, riches: Is Biogen the Cinderella of biotechs?
Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.
By Michael Gibney • Oct. 27, 2022 -
Justin Sullivan/Staff via Getty Images
Q&ANobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development
The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.
By Karissa Waddick • Oct. 26, 2022 -
Permission granted by Tasuku Kitada
ProfileA longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level
The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.
By Alexandra Pecci • Oct. 25, 2022 -
Stock via Getty Images
Beyond cancer: Scientists push CAR-T cell therapies into new frontiers
Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.
By Kelly Bilodeau • Oct. 24, 2022 -
Stock via Getty Images
OpinionWhat’s keeping pharma leaders up at night
C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.
By Taren Grom • Oct. 21, 2022 -
Stock illustration via Getty Images
ProfileHow a company aimed at bringing the woolly mammoth back to life spun off a startup that could speed drug development
Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.
By Alexandra Pecci • Oct. 20, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Exscientia’s Charlotte Deane
Is the industry ready for a biologic discovery revolution? Charlotte Deane, chief scientist of biologics AI at Exscientia, thinks so.
By Taren Grom • Oct. 19, 2022 -
Stock via Getty Images
5 impactful drug trial failures from the last year
Major recent trial flops and what they mean for companies, patients and the industry.
By Meagan Parrish • Oct. 19, 2022 -
Stock via Getty Images
A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers
Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.
By Kelly Bilodeau • Oct. 18, 2022 -
Stock via Getty Images
The Novartis U.S. Foundation’s president on the ‘magical piece’ of its 10-year health equity plan
Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.
By Meagan Parrish • Oct. 17, 2022 -
Permission granted by BMS / Ryan Moslin
Q&AHe helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma
Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.
By Michael Gibney • Oct. 17, 2022 -
Permission granted by Park & Battery
Sponsored by PPDSurvey: The Top 5 Innovations and New Operational Strategies in Pharmaceutical R&D
According to a recent survey conducted by PPD, part of Thermo Fisher Scientific, 98% of drug developers report that, in the wake of COVID-19, they have embraced a wealth of new strategies across the entire clinical trial lifecycle – from adaptive trial design to big data. Find out how to apply these trends to your innovative clinical programs.
Oct. 17, 2022 -
Permission granted by GoodRx
Sponsored by GoodRxDoes your copay program factor in differences across specialties? GoodRx analysis shows it should.
New findings reveal an out-of-pocket cost gap between brand-name and generic prescriptions. To address this gap, GoodRx is partnering with pharmaceutical companies to improve cost transparency and communication between patients and providers.
Oct. 17, 2022 -
iStock via Getty Images
Making MovesBIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech
What these life science organizations’ latest executive-level appointments mean for the industry.
By Karissa Waddick • Oct. 14, 2022 -
iStock via Getty Images
Q&A // First 90 DaysComing out of stealth, RIGImmune aims to catch up with ever-mutating viruses
President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.
By Kelly Bilodeau • Oct. 13, 2022 -
iStock via Getty Images
Robotic pills could open a world of possibilities for the biologics market
As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions.
By Karissa Waddick • Oct. 13, 2022 -
Permission granted by Ameet Mallik
Q&AWhere the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology
The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.
By Meagan Parrish • Oct. 12, 2022 -
skynesher via Getty Images
Q&A // Biotech SpotlightCitius Pharmaceuticals sees golden opportunities in late-stage specialty assets
CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.
By Karissa Waddick • Oct. 11, 2022
Previous
